Generic penetration in the retail atypical antipsychotic market

Susan Lenderts; Amir H. Kalali; Peter Buckley

Generic penetration in the retail atypical antipsychotic market

Susan Lenderts, Amir H. Kalali, Peter Buckley

Graduate Studies

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

In this article, we explore the penetration of generic atypical antipsychotics in the United States market before and after the availability of generic risperidone in July 2008. Analysis suggests that, overall, generic penetration into the atypical antipsychotic market has grown from approximately three percent in January 2008 to more than 25 percent in December 2009. Similar trends are uncovered when branded and generic prescriptions are analyzed by specialty.

Original language	English (US)
Pages (from-to)	9-10
Number of pages	2
Journal	Psychiatry (Edgemont)
Volume	7
Issue number	3
State	Published - Mar 2010

Keywords

Atypical antipsychotic
Brand
Generic
Generic penetration
Prescription
Psychiatrists
Risperidone
Trade

ASJC Scopus subject areas

Psychiatry and Mental health

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{4e00c89f83b24115b3fd2f8070bdce90,

title = "Generic penetration in the retail atypical antipsychotic market",

abstract = "In this article, we explore the penetration of generic atypical antipsychotics in the United States market before and after the availability of generic risperidone in July 2008. Analysis suggests that, overall, generic penetration into the atypical antipsychotic market has grown from approximately three percent in January 2008 to more than 25 percent in December 2009. Similar trends are uncovered when branded and generic prescriptions are analyzed by specialty.",

keywords = "Atypical antipsychotic, Brand, Generic, Generic penetration, Prescription, Psychiatrists, Risperidone, Trade",

author = "Susan Lenderts and Kalali, {Amir H.} and Peter Buckley",

year = "2010",

month = mar,

language = "English (US)",

volume = "7",

pages = "9--10",

journal = "Psychiatry (Edgemont)",

issn = "1550-5952",

publisher = "Matrix Medical Communications",

number = "3",

}

TY - JOUR

T1 - Generic penetration in the retail atypical antipsychotic market

AU - Lenderts, Susan

AU - Kalali, Amir H.

AU - Buckley, Peter

PY - 2010/3

Y1 - 2010/3

N2 - In this article, we explore the penetration of generic atypical antipsychotics in the United States market before and after the availability of generic risperidone in July 2008. Analysis suggests that, overall, generic penetration into the atypical antipsychotic market has grown from approximately three percent in January 2008 to more than 25 percent in December 2009. Similar trends are uncovered when branded and generic prescriptions are analyzed by specialty.

AB - In this article, we explore the penetration of generic atypical antipsychotics in the United States market before and after the availability of generic risperidone in July 2008. Analysis suggests that, overall, generic penetration into the atypical antipsychotic market has grown from approximately three percent in January 2008 to more than 25 percent in December 2009. Similar trends are uncovered when branded and generic prescriptions are analyzed by specialty.

KW - Atypical antipsychotic

KW - Brand

KW - Generic

KW - Generic penetration

KW - Prescription

KW - Psychiatrists

KW - Risperidone

KW - Trade

UR - http://www.scopus.com/inward/record.url?scp=77956077489&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956077489&partnerID=8YFLogxK

M3 - Article

C2 - 20436769

AN - SCOPUS:77956077489

SN - 1550-5952

VL - 7

SP - 9

EP - 10

JO - Psychiatry (Edgemont)

JF - Psychiatry (Edgemont)

IS - 3

ER -

Generic penetration in the retail atypical antipsychotic market

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Other files and links

Fingerprint

Cite this